嵌合抗原受体
医学
疾病
大流行
免疫学
造血干细胞移植
人口
冠状病毒
血液学
接种疫苗
造血细胞
重症监护医学
作者
Akshay Sharma,Neel S. Bhatt,Diego R. Hijano
出处
期刊:Current Opinion in Hematology
[Ovid Technologies (Wolters Kluwer)]
日期:2021-11-01
卷期号:28 (6): 394-400
被引量:2
标识
DOI:10.1097/moh.0000000000000683
摘要
To discuss the clinical experience of coronavirus disease 2019 (COVID-19) in hematopoietic cell transplant and chimeric antigen receptor T-cell therapy recipients over the past year and to identify key knowledge gaps for future research.Immunocompromised individuals and those with chronic health conditions are especially susceptible to infections, which have had a disproportionate impact on health outcomes during the COVID-19 pandemic. Several studies have evaluated the clinical characteristics and outcomes of transplant and cellular therapy (TCT) recipients who developed COVID-19. Age, sex, comorbid conditions, and social determinants of health are important predictors of the risk of severe acute respiratory syndrome coronavirus 2 infection and of the eventual severity of the disease. Various treatment approaches have been investigated over the last year. The paradigm of management strategies continues to evolve as more experience is accumulated.In this review, we summarize some important findings as they relate to the clinical characteristics of TCT recipients who develop COVID-19. We also discuss some treatment approaches that are currently recommended and opine on vaccination in this population.
科研通智能强力驱动
Strongly Powered by AbleSci AI